THE HAGUE, Netherlands (AP) – The European Union’s Medicines Agency has recommended approving the use of anti-inflammatory drugs to treat adults hospitalized with severe COVID-19. The decision by the European Medicines Agency on Monday must be confirmed by the EU’s executive committee. It expands the use of the drug RoActemra, manufactured by Swiss pharmaceutical giant Roche, which is currently used to treat forms of arthritis. The EMA says it can now also be used for adult COVID-19 patients who are being treated with corticosteroids and need supplemental oxygen or mechanical ventilation. The drug, given intravenously, reduces a protein called interleukin-6 that is often found in excess in COVID-19 patients.
https://kesq.com/news/ap-national-news/2021/12/06/eu-drug-agency-recommends-approving-covid-19-treatment-2/ EU Medicines Agency recommends approval for COVID-19 treatment